Junod

Denosumab, the active ingredient in Junod, is a monoclonal antibody presented as a solution for injection for subcutaneous use. It treats postmenopausal osteoporosis, bone loss in men receiving androgen deprivation therapy, and helps prevent skeletal-related events in patients with bone metastases by inhibiting osteoclast-mediated bone resorption, thereby improving bone mineral density.

GNH USA supplies Junod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with distribution networks across Europe, Asia and the Americas, and complying with all relevant regulatory standards.

Denosumab is used to treat conditions characterized by increased bone resorption.

- Postmenopausal osteoporosis: reduces fracture risk and increases bone mineral density in postmenopausal women. - Bone loss in men receiving androgen deprivation therapy: prevents bone loss associated with ADT in prostate cancer patients. - Skeletal-related events in patients with bone metastases: lowers incidence of fractures, spinal cord compression, and need for radiation or surgery to bone.

Denosumab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Musculoskeletal pain: aches in joints, muscles or bones. - Upper respiratory infections: nasopharyngitis or sinusitis. - Dermatologic reactions: rash or eczema.

Serious or Rare Side Effects: - Hypocalcemia: low blood calcium levels, potentially symptomatic. - Osteonecrosis of the jaw (ONJ): exposed bone in the jaw region. - Atypical femoral fractures: unusual fractures of the thigh bone. - Severe hypersensitivity: anaphylaxis or severe skin reactions.

Before initiating therapy with Denosumab, several precautions should be considered to ensure safe use. - Calcium and vitamin D supplementation: ensure adequate intake to reduce hypocalcemia risk. - Baseline calcium assessment: check serum calcium levels prior to first dose. - Dental examination: obtain dental assessment before treatment to lower ONJ risk. - Renal function monitoring: evaluate kidney function, especially in patients with severe impairment. - Concomitant medications: review use of other bone‑active agents such as bisphosphonates. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab can interact with other medicines, affecting calcium balance or bone health.

Major Interactions (Avoid): - Calcium‑lowering agents: concurrent use with high‑dose calcitonin may increase hypocalcemia risk. - Immunosuppressants: may reduce efficacy of Denosumab in bone protection.

Moderate Interactions (Monitor Closely): - Bisphosphonates: sequential therapy may increase risk of hypocalcemia; monitor calcium. - Hormone therapy: aromatase inhibitors may have additive effects on bone. - Anticonvulsants: enzyme‑inducing drugs can affect vitamin D metabolism, influencing calcium levels.